The BONSAI study, sponsored by the National Institute on Aging, aims to explore the effects of ibuprofen on biomarkers linked to Alzheimer's Disease. Given the increasing prevalence of Alzheimer's and the growing demand for effective treatments, this study could provide critical insights into the potential repurposing of ibuprofen as a therapeutic option. If successful, the findings may open avenues for commercialization in the neurodegenerative disease market, which is projected to grow significantly. However, the competitive landscape includes numerous ongoing trials targeting similar pathways, necessitating careful monitoring of emerging data and competitor strategies.